The four major factors predisposing individuals to community-acquired pneumonia (CAP)
are chronic obstructive pulmonary disease, congestive heart failure, diabetes, and a high …

Background Most guidelines have been proposing, for more than 15 years, a β-lactam
combined with either a quinolone or a macrolide as empirical, first-line therapy of severe …

Lower respiratory tract infections are the major cause of death due to infectious disease in
the developed and developing world. Despite substantial progress in defining pathogens …

Background Ceftriaxone (CTRX) and ampicillin/sulbactam (ABPC/SBT) are recommended
by various guidelines as the first-line antibiotics for community-acquired pneumonia (CAP) …

Data comparing the treatment outcomes of the two most frequently recommended empirical
antibiotic regimens for community-acquired pneumonia (CAP)—combination therapy with an …

Objectives Ceftriaxone is recommended as first-line antibiotic treatment (with the addition of
macrolide) for hospitalised adults with community acquired pneumonia (CAP). Narrower …

Five hundred ninety patients were enrolled in a prospective, multicenter, randomized trial
comparing the efficacy and safety of 7 to 14 days of levofloxacin treatment with that of …

Objectives Several studies have compared the clinical effect of β-lactam/macrolide (BLM)
dual therapy versus β-lactam (BL) monotherapy in community-acquired pneumonia (CAP) …

Objective: This study presents a cost-minimisation analysis of moxifloxacin compared to
combination treatment with levofloxacin and ceftriaxone in patients hospitalised with …

Background Increasing use of broad-spectrum antibiotics in the community, including
fluoroquinolones, has been reported, despite concerns for developing antibiotic resistant …